Meta-analysis of the efficacy and safety of sintilimab for treating advanced non-small cell lung cancer.
Ontology highlight
ABSTRACT: Lung cancer is the leading cause of death from malignant tumors in China, and non-small cell lung cancer (NSCLC) accounts for >80% of all types of lung cancer. Novel immunotherapeutic agents targeting programmed death protein-1 (PD-1) and its ligands [programmed death ligands (PD-L)1 and 2] have emerged as important therapeutic measures and trends in the treatment of advanced NSCLC. Sintilimab (trade name, Daboshu) is a humanized IgG4 monoclonal antibody targeting PD-1 that was developed by Innovent Biologics and Eli Lilly and Company. Studies have shown that sintilimab has the characteristics of high affinity, long-lasting stability and an increased target occupancy rate, and that it is a broad-spectrum drug. The present study uses a meta-analysis to evaluate the safety and efficacy of si
SUBMITTER: Xie J
PROVIDER: S-EPMC9580245 | biostudies-literature | 2022 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA